{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,21]],"date-time":"2026-06-21T07:58:56Z","timestamp":1782028736868,"version":"3.54.5"},"reference-count":32,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2011,11,16]],"date-time":"2011-11-16T00:00:00Z","timestamp":1321401600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hematology Reports"],"abstract":"<jats:p>The determination of prognosis for B-Non-Hodgkin\u2019s lymphoma (NHL) is known to be related to the multiple differences in tumor cell biology. Bcl-2 and Bcl-6 are two markers linked to germinal center B cells. Both markers are thought to have an effect on prognosis of mature B-cell neoplasms. Forty-four patients with chronic B-cell neoplasm were included; Bcl-2 and Bcl-6 expression by immunohistochemistry was examined. Bcl-2 protein was positive in 36.4% (16 of 44) of cases (62.5% of follicular lymphoma, 16.7% of mantle cell lymphoma and 30% of diffuse large B-cell lymphoma); the positive group implying a bad prognostic effect of the marker in NHL. Bcl-6 was positive in 13.6% (6 of 44) of cases (11.1% of mantle cell lymphoma and 40% of diffuse large B-cell lymphoma) and its positivity implies a better disease course. Bcl-2 and Bcl-6 can be used as prognostic marker in NHL.<\/jats:p>","DOI":"10.4081\/hr.2011.e26","type":"journal-article","created":{"date-parts":[[2011,12,2]],"date-time":"2011-12-02T00:28:24Z","timestamp":1322785704000},"page":"e26","source":"Crossref","is-referenced-by-count":11,"title":["Significance of Bcl-2 and Bcl-6 Immunostaining in B-Non Hodgkin's lymphoma"],"prefix":"10.3390","volume":"3","author":[{"given":"Hanan Mohamed","family":"Mahmoud","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasmin Nabil","family":"Elsakhawy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2011,11,16]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3322\/CA.2007.0010","article-title":"Cancer statistics","volume":"58","author":"Jemal","year":"2008","journal-title":"CA Cancer J Clin"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.anndiagpath.2007.08.002","article-title":"Pathology of chronic lymphocytic leukemia: an update","volume":"11","author":"Inamdar","year":"2007","journal-title":"Ann Diagn Pathol"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1056\/NEJMra020067","article-title":"Molecular diagnosis of the hematologic cancers","volume":"348","author":"Staudt","year":"2003","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1200\/JCO.2005.03.4264","article-title":"BCL-2 expression is a prognostic marker for the activated B-cell-like type of diffuse large B-cell lymphoma","volume":"24","author":"Iqbal","year":"2006","journal-title":"J Clin Oncol"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1097\/00125480-200107000-00003","article-title":"Lymphoma immunophenotyping: a new era in paraffin-section immunohistochemistry","volume":"8","author":"Hsi","year":"2001","journal-title":"Adv Anat Pathol"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1309\/TNKL7GDC66R9WPV5","article-title":"Expression of Bcl-6 and CD10 protein is associated with longer overall survival and time to treatment failure in follicular lymphoma","volume":"121","author":"Bilalovic","year":"2004","journal-title":"Am J Clin Pathol"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1111\/j.1365-2559.2003.01758.x","article-title":"Variability in immunophenotype in diffuse large B-cell lymphoma and its clinical relevance","volume":"43","author":"De Leval","year":"2003","journal-title":"Histopathology"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s12308-009-0044-x","article-title":"A cytomorphological and immunohistochemical profile of aggressive B-cell lymphoma: high clinical impact of a cumulative immunohistochemical outcome predictor score","volume":"2","author":"H\u00f6ller","year":"2009","journal-title":"J Hematop"},{"key":"ref9","first-page":"722","article-title":"Immunohistochemical expression of CD23 and CD40 may identify prognostically favorable subgroups of diffuse large B-cell lymphoma: a Nordic Lymphoma Group Study","volume":"9","author":"Linderoth","year":"2003","journal-title":"Clin Cancer Res"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.1182\/blood-2005-01-0016","article-title":"Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone","volume":"106","author":"Hiddemann","year":"2005","journal-title":"Blood"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.jaad.2008.12.045","article-title":"Intravascular large B-cell lymphoma: Remission after rituximab-cyclophosphamide, doxorubicin, vincristine, and prednisolone chemotherapy","volume":"61","author":"Horvath","year":"2009","journal-title":"J Am Acad Dermatol"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J Clin Oncol"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.crad.2007.10.005","article-title":"Response assessment in lymphoma","volume":"63","author":"Hampson","year":"2008","journal-title":"Clin Radiol"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/ajh.10017","article-title":"Detection of relapse in non-Hodgkin's lymphoma: Role of routine follow-up studies","volume":"69","author":"Elis","year":"2002","journal-title":"Am J Hematol"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1046\/j.1365-2141.2001.02727.x","article-title":"Bcl-2 expression in non-Hodgkin's lymphomas is not associated with Bcl-2 gene rearrangements","volume":"113","author":"Papakonstantinous","year":"2001","journal-title":"Brit J Haemat"},{"key":"ref16","first-page":"560","article-title":"Staining for Bcl-2 protein helps to distinguish benign from malignant lymphoid aggregates in bone marrow biopsies","volume":"7","author":"Ben-Ezra","year":"1994","journal-title":"Mod Pathol"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1309\/W3QX-WJ1C-WG2K-225V","article-title":"The usefulness of immunohistochemistry in the diagnosis of follicular lymphoma in bone marrow biopsy specimens","volume":"117","author":"West","year":"2002","journal-title":"Am J Clin Pathol"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1385\/MO:18:1:15","article-title":"Prognostic significance of Ki-67 nuclear proliferative antigen, Bcl-2 protein, and p53 expression in follicular and diffuse large B-cell lymphoma","volume":"18","author":"Llanos","year":"2001","journal-title":"Med Oncol"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1136\/jcp.48.1.18","article-title":"Expression of the Bcl-2 protein in B-cell lymphomas arising from mucosa-associated lymphoid tissue","volume":"48","author":"Navratil","year":"1995","journal-title":"J Clin Pathol"},{"key":"ref20","first-page":"39","article-title":"Non-Hodgkin's lymphomas: immunologic prognostic studies","volume":"28","author":"Hadzi-Pecova","year":"2007","journal-title":"Prilozi"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1182\/blood.V87.1.265.265","article-title":"Prognostic significance of Bcl-2 protein expression in aggressive non-Hodgkin's lymphoma. Groupe d'Etude des Lymphomes de l'Adulte (GELA)","volume":"87","author":"Hermine","year":"1996","journal-title":"Blood"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1200\/JCO.1994.12.1.149","article-title":"Clinical significance of Bcl-2-MBR gene rearrangement and protein expression in diffuse large-cell non-Hodgkin's lymphoma: an analysis of 83 cases","volume":"12","author":"Tang","year":"1994","journal-title":"J Clin Oncol"},{"key":"ref23","first-page":"370","article-title":"The Bcl-2 gene translocation t(14;18) identifies a subgroup of patients with diffuse large cell lymphoma having an indolent clinical course with late relapse","volume":"13","author":"Miller","year":"1994","journal-title":"Proc Am Soc Clin Oncol"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/bjc.1994.61","article-title":"p53 and Bcl-2 expression in high-grade B-cell lymphomas: correlation with survival time","volume":"69","author":"Piris","year":"1994","journal-title":"Br J Cancer"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1590\/S1516-31802010000100004","article-title":"Bcl-2 protein frequency in patients with high-risk diffuse large B-cell lymphoma","volume":"128","author":"Hallack","year":"2010","journal-title":"Sao Paulo Med J"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1046\/j.1365-2141.2002.03435.x","article-title":"Rearrangement of the BCL-6 locus at 3q27 is an independent poor prognostic factor in nodal diffuse large B-cell lymphoma","volume":"117","author":"Barrans","year":"2002","journal-title":"Br J Haematol"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"10209","DOI":"10.1073\/pnas.180316097","article-title":"Ongoing immunoglobulin somatic mutation in germinal center B cell-like but not in activated B cell-like diffuse large cell lymphomas","volume":"97","author":"Lossos","year":"2000","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1038\/modpathol.3800396","article-title":"Evaluation of immunophenotype in diffuse large B-cell lymphoma and its impact on prognosis","volume":"18","author":"Berglund","year":"2005","journal-title":"Mod Pathol"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1097\/00000478-200006000-00010","article-title":"CD10 and BCL-6 expression in paraffin sections of normal lymphoid tissue and B-cell lymphomas","volume":"24","author":"Dogan","year":"2000","journal-title":"Am J Surg Pathol"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1182\/blood-2002-04-1286","article-title":"(2003): Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma","volume":"101","author":"Colomo","year":"2003","journal-title":"Blood"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1111\/j.1440-1827.2006.01986.x","article-title":"Mantle cell lymphoma in Taiwan: clinicopathological and molecular study of 21 cases including one cyclin D1-negative tumor expressing cyclin D2","volume":"56","author":"Chuang","year":"2006","journal-title":"Pathol Int"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1097\/PAI.0b013e3181bb9edf","article-title":"BCL-6, MUM1, and CD10 expression in mantle cell lymphoma","volume":"18","author":"Gualco","year":"2010","journal-title":"Appl Immunohistochem Mol Morphol"}],"container-title":["Hematology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2038-8330\/3\/3\/e26\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,23]],"date-time":"2022-02-23T06:38:51Z","timestamp":1645598331000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2038-8330\/3\/3\/e26"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,11,16]]},"references-count":32,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2011,10]]}},"alternative-id":["hr.2011.e26"],"URL":"https:\/\/doi.org\/10.4081\/hr.2011.e26","relation":{},"ISSN":["2038-8330"],"issn-type":[{"value":"2038-8330","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,11,16]]}}}